{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:05:15Z","timestamp":1793657115924,"version":"4.5.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bioorg.2021.105262","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T13:51:05Z","timestamp":1628689865000},"page":"105262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide"],"prefix":"10.1016","volume":"115","author":[{"given":"Marwa H.","family":"El-Wakil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Teleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa.M.","family":"Abu-Serie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald W.","family":"Zamponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105262_b0005","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"10.1016\/j.bioorg.2021.105262_b0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105262_b0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging Topoisomerases: Lessons and Challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2021.105262_b0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.bioorg.2021.105262_b0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1568011054222364","article-title":"Etoposide, topoisomerase II and cancer","volume":"5","author":"Baldwin","year":"2005","journal-title":"Curr. Med. Chem. - Anti-Cancer Agents."},{"key":"10.1016\/j.bioorg.2021.105262_b0030","doi-asserted-by":"crossref","unstructured":"A. Flemming, Finding the perfect combination, Nat. Rev. Drug Discov. 14 (2015) 13. doi:10.1038\/nrd4524.","DOI":"10.1038\/nrd4524"},{"issue":"7","key":"10.1016\/j.bioorg.2021.105262_b0035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105262_b0040","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/j.bbamem.2015.03.034","article-title":"Targeting ion channels for cancer therapy by repurposing the approved drugs","volume":"1848","author":"Kale","year":"2015","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105262_b0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrc2171","article-title":"Calcium and cancer: targeting Ca2+ transport","volume":"7","author":"Monteith","year":"2007","journal-title":"Nat. Rev. Cancer."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105262_b0050","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.bbamem.2014.08.016","article-title":"Altered calcium signaling in cancer cells","volume":"1848","author":"Stewart","year":"2015","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105262_b0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2017.18","article-title":"The calcium-cancer signalling nexus","volume":"17","author":"Monteith","year":"2017","journal-title":"Nat. Rev. Cancer."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105262_b0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2016.11.001","article-title":"Targeting calcium signaling in cancer therapy","volume":"7","author":"Cui","year":"2017","journal-title":"Acta Pharm. Sin. B."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105262_b0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/glia.20063","article-title":"Expression of T-type calcium channel splice variants in human glioma","volume":"48","author":"Latour","year":"2004","journal-title":"Glia."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105262_b0070","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bcp.2012.12.017","article-title":"Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells","volume":"85","author":"Valerie","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105262_b0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ceca.2007.03.006","article-title":"T-type Ca2+ channel expression in human esophageal carcinomas: A functional role in proliferation","volume":"43","author":"Lu","year":"2008","journal-title":"Cell Calcium."},{"key":"10.1016\/j.bioorg.2021.105262_b0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biocel.2019.01.008","article-title":"T-type calcium channels: From molecule to therapeutic opportunities","volume":"108","author":"Weiss","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105262_b0085","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bmcl.2015.12.010","article-title":"In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells","volume":"26","author":"Byun","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105262_b0090","doi-asserted-by":"crossref","first-page":"115491","DOI":"10.1016\/j.bmc.2020.115491","article-title":"Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers","volume":"28","author":"Nam","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2021.105262_b0095","doi-asserted-by":"crossref","first-page":"9769","DOI":"10.1021\/acs.jmedchem.7b01236","article-title":"Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies","volume":"60","author":"Bezen\u00e7on","year":"2017","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2021.105262_b0100","doi-asserted-by":"crossref","first-page":"8398","DOI":"10.1021\/acs.jmedchem.6b00756","article-title":"Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers","volume":"59","author":"Remen","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105262_b0105","unstructured":"O. Benzencon, J. Gatfield, B. Heidmann, R. Siegrist, S. Stamm, O. Bezen\u00e7on, J. Gatfield, B. Heidmann, R. Siegrist, S. Stamm, Triazole Compounds As T-Type Calcium Channel Blockers, WO2016041892A1, 2016."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105262_b0110","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/cc100041m","article-title":"Exploration of Novel 2-Alkylimino-1,3-thiazolines: T-Type Calcium Channel Inhibitory Activity","volume":"12","author":"Han","year":"2010","journal-title":"J. Comb. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105262_b0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1124\/mol.112.079715","article-title":"Common Mechanisms of Drug Interactions with Sodium and T-Type Calcium Channels","volume":"82","author":"Bladen","year":"2012","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105262_b0120","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00424-013-1376-z","article-title":"Synthesis and Evaluation of 1,4-Dihydropyridine Derivatives with Calcium Channel Blocking Activity","volume":"466","author":"Bladen","year":"2014","journal-title":"Pfl\u00fcgers Arch. - Eur. J. Physiol."},{"key":"10.1016\/j.bioorg.2021.105262_b0125","doi-asserted-by":"crossref","first-page":"102915","DOI":"10.1016\/j.bioorg.2019.04.009","article-title":"Synthesis of some new C2 substituted dihydropyrimidines and their electrophysiological evaluation as L-\/T-type calcium channel blockers","volume":"88","author":"Teleb","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105262_b0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jare.2014.10.006","article-title":"V Modolo, A mini-review on Biginelli adducts with notable pharmacological properties","volume":"6","author":"de F\u00e1tima","year":"2015","journal-title":"J. Adv. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105262_b0135","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bmc.2017.02.015","article-title":"Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain","volume":"25","author":"Teleb","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105262_b0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmech.2017.03.080","article-title":"Synthesis of new N3-substituted dihydropyrimidine derivatives as L-\/T- type calcium channel blockers","volume":"134","author":"Teleb","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105262_b0145","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bioorg.2018.10.054","article-title":"Design, synthesis and pharmacological evaluation of some substituted dihydropyrimidines with L-\/T-type calcium channel blocking activities","volume":"83","author":"Teleb","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105262_b0150","doi-asserted-by":"crossref","first-page":"104393","DOI":"10.1016\/j.bioorg.2020.104393","article-title":"New chalcone-tethered 1,3,5-triazines potentiate the anticancer effect of cisplatin against human lung adenocarcinoma A549 cells by enhancing DNA damage and cell apoptosis","volume":"105","author":"El-Wakil","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105262_b0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0040-4039(01)88217-4","article-title":"The vilsmeier-haack reaction - III Cyclization of hydrazones to pyrazoles","volume":"10","author":"Kira","year":"1969","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2021.105262_b0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejmech.2015.02.038","article-title":"New heterocyclic hybrids of pyrazole and its bioisosteres: Design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents","volume":"94","author":"Bekhit","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105262_b0165","doi-asserted-by":"crossref","first-page":"104386","DOI":"10.1016\/j.bioorg.2020.104386","article-title":"Design, synthesis, biological evaluation and in silico studies of certain aryl sulfonyl hydrazones conjugated with 1,3-diaryl pyrazoles as potent metallo-\u03b2-lactamase inhibitors","volume":"105","author":"Shaaban","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105262_b0170","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ejmech.2013.12.039","article-title":"1-Phenyl-1H- and 2-phenyl-2H-1,2,3-triazol derivatives: Design, synthesis and inhibitory effect on alpha-glycosidases","volume":"74","author":"Gonzaga","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105262_b0175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1134\/S1070428009050030","article-title":"V Shamanin, Tautomerism and conformational isomerism of mercaptoacetylhydrazones of aliphatic and aromatic aldehydes","volume":"45","author":"Ershov","year":"2009","journal-title":"Russ. J. Org. Chem."},{"key":"10.1016\/j.bioorg.2021.105262_b0180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bioorg.2017.06.009","article-title":"Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors","volume":"73","author":"El-Wakil","year":"2017","journal-title":"Bioorg. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2021.105262_b0185","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.tetlet.2009.02.027","article-title":"Facile conversion of Biginelli 3,4-dihydropyrimidin-2(1H)-thiones to 2-(2-hydroxy-2-arylvinyl) dihydropyrimidines via Eschenmoser coupling","volume":"50","author":"Singh","year":"2009","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2021.105262_b0190","article-title":"Synthesis, Spectroscopic Studies and Keto-Enol Tautomerism of Novel 1,3,4-Thiadiazole Derivative Containing 3-Mercaptobutan-2-one and Quinazolin-4-one Moieties","volume":"25","author":"Jalal","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.bioorg.2021.105262_b0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0091-679X(08)61113-9","article-title":"Application of patch clamp methods to the study of calcium currents and calcium channels","volume":"40","author":"Leech","year":"1994","journal-title":"Methods Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105262_b0200","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/0008-5472.CAN-17-3061","article-title":"T-type Ca2+Channels: T for Targetable","volume":"78","author":"Sall\u00e1n","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105262_b0205","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.bmcl.2011.11.083","article-title":"In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor","volume":"22","author":"Kang","year":"2012","journal-title":"Bioorgan. Med. Chem. Lett."},{"issue":"1-2","key":"10.1016\/j.bioorg.2021.105262_b0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods."},{"key":"10.1016\/j.bioorg.2021.105262_b0215","doi-asserted-by":"crossref","first-page":"12361","DOI":"10.1038\/srep12361","article-title":"A strategy for the identification of combinatorial bioactive compounds contributing to the holistic effect of herbal medicines","volume":"5","author":"Long","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105262_b0220","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1541-7786.MCR-13-0485","article-title":"T-Type Ca2+Channel Inhibition Induces p53-Dependent Cell Growth Arrest and Apoptosis through Activation of p38-MAPK in Colon Cancer Cells","volume":"12","author":"Dziegielewska","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105262_b0225","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1038\/s41598-017-06692-0","article-title":"ADME-Space: a new tool for medicinal chemists to explore ADME properties","volume":"7","author":"Bocci","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.105262_b0230","doi-asserted-by":"crossref","unstructured":"V. Nogueira Holanda, W. Vicente da Silva, P. Henrique do Nascimento, S. Ruschi Bergamachi Silva, P. Euz\u00e9bio Cabral Filho, S. Porto de Oliveira Assis, C. Augusto da Silva, R. Nascimento de Oliveira, R. Celia Bressan Queiroz de Figueiredo, V. Lucia de Menezes Lima, Antileishmanial effects of 4-phenyl-1-[2-(phthalimido-2-yl)ethyl]-1H-1,2,3-triazole (PT4) derivative on Leishmania amazonensis and Leishmania braziliensis: In silico ADMET, in vitro activity, docking and molecular dynamic simulations, Bioorg. Chem. (2020) 104437. doi:https:\/\/doi.org\/10.1016\/j.bioorg.2020.104437.","DOI":"10.1016\/j.bioorg.2020.104437"},{"key":"10.1016\/j.bioorg.2021.105262_b0235","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.105262_b0240","unstructured":"S. Lee, I.H. Lee, H. joong Kim, G.S. Chang, J.E. Chung, K.T. No, The PreADME Approach: Web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties, Euro QSAR 2002 - Des. Drugs Crop Prot. Process. Probl. Solut. (2002) 418\u2013420."},{"key":"10.1016\/j.bioorg.2021.105262_b0245","doi-asserted-by":"crossref","unstructured":"D.E. V Pires, T.L. Blundell, D.B. Ascher, pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures, J. Med. Chem. 58 (2015) 4066\u20134072. doi:10.1021\/acs.jmedchem.5b00104.","DOI":"10.1021\/acs.jmedchem.5b00104"},{"key":"10.1016\/j.bioorg.2021.105262_b0250","doi-asserted-by":"crossref","unstructured":"R. Callaghan, F. Luk, M. Bebawy, Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?, Drug Metab. Dispos. 42 (2014) 623 LP-631. doi:10.1124\/dmd.113.056176.","DOI":"10.1124\/dmd.113.056176"},{"key":"10.1016\/j.bioorg.2021.105262_b0255","doi-asserted-by":"crossref","unstructured":"Y. D\u00f6nmez, L. Akhmetova, \u00d6.D. \u0130\u015feri, M.D. Kars, U. G\u00fcnd\u00fcz, Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells, Cancer Chemother. Pharmacol. 67 (2011) 823\u2013828. doi:10.1007\/s00280-010-1385-y.","DOI":"10.1007\/s00280-010-1385-y"},{"key":"10.1016\/j.bioorg.2021.105262_b0260","doi-asserted-by":"crossref","unstructured":"Z. Bibi, Role of cytochrome P450 in drug interactions, Nutr. Metab. (Lond). 5 (2008) 27. doi:10.1186\/1743-7075-5-27.","DOI":"10.1186\/1743-7075-5-27"},{"key":"10.1016\/j.bioorg.2021.105262_b0265","doi-asserted-by":"crossref","unstructured":"J.R. Amsden, P.O. Gubbins, Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy, Expert Opin. Drug Metab. Toxicol. 13 (2017) 1135\u20131146. doi:10.1080\/17425255.2017.1391213.","DOI":"10.1080\/17425255.2017.1391213"},{"key":"10.1016\/j.bioorg.2021.105262_b0270","doi-asserted-by":"crossref","unstructured":"T. Sato, H. Yuki, K. Ogura, T. Honma, Construction of an integrated database for hERG blocking small molecules, PLoS One. 13 (2018) e0199348. https:\/\/doi.org\/10.1371\/journal.pone.0199348.","DOI":"10.1371\/journal.pone.0199348"},{"key":"10.1016\/j.bioorg.2021.105262_b0275","doi-asserted-by":"crossref","unstructured":"Y. Jing, A. Easter, D. Peters, N. Kim, I.J. Enyedy, In silico prediction of hERG inhibition, Future Med. Chem. 7 (2015) 571\u2013586. doi:10.4155\/fmc.15.18.","DOI":"10.4155\/fmc.15.18"},{"key":"10.1016\/j.bioorg.2021.105262_b0280","doi-asserted-by":"crossref","unstructured":"C.R. Clark, R.H. McKee, J.J. Freeman, D. Swick, S. Mahagaokar, G. Pigram, L.G. Roberts, C.J. Smulders, P.W. Beatty, A GHS-consistent approach to health hazard classification of petroleum substances, a class of UVCB substances, Regul. Toxicol. Pharmacol. 67 (2013) 409\u2013420. doi:https:\/\/doi.org\/10.1016\/j.yrtph.2013.08.020.","DOI":"10.1016\/j.yrtph.2013.08.020"},{"key":"10.1016\/j.bioorg.2021.105262_b0285","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/mutage\/gey028","article-title":"Data-based review of QSARs for predicting genotoxicity: the state of the art","volume":"34","author":"Benigni","year":"2019","journal-title":"Mutagenesis."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821006398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821006398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:32:46Z","timestamp":1758616366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821006398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":57,"alternative-id":["S0045206821006398"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105262","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105262"}}